Anteris Technologies Ltd (AMEUF)
Stock analysis · OTC · Healthcare · Medical - Devices
Anteris Technologies Ltd (AMEUF) is a publicly traded company in the Healthcare sector. Latest price: $5.70. Market cap $120.50M. Trailing PE -1.33. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →Earnings
Proprietary Signals
About Anteris Technologies Ltd
Anteris Technologies Ltd. is a medical device company focused on structural heart solutions. The firm manufactures and commercializes ADAPT, an advanced regenerative tissue product. Additionally, Anteris is actively developing DurAVRTM, a novel 3D, single-piece aortic valve designed to treat aortic stenosis. The company also conducts research and development in the broader field of regenerative medicines. Established in 1999, it changed its name from Admedus Limited to Anteris Technologies Ltd. in May 2020 and is headquartered in Toowong, Australia.
Valuation
| P/E (TTM) | -1.33× |
|---|---|
| P/S (TTM) | 39.19× |
| P/B | 1.62× |
| P/FCF (TTM) | -1.67× |
| EV / EBITDA | -0.48× |
| EV / Sales | 13.64× |
| Earnings Yield | -75.18% |
| Free Cash Flow Yield | -59.96% |
Fundamentals
| Enterprise Value | $59.56M |
|---|---|
| Revenue (TTM) | $4.37M |
| Net Income (TTM) | -$128.66M |
| Free Cash Flow (TTM) | -$102.48M |
| Net Debt | -$111.59M |
| Working Capital | $93.86M |
| Gross Margin | 46.84% |
| Operating Margin | -2899.45% |
| Net Margin | -2822.46% |
| Return on Equity | -189.63% |
| Return on Invested Capital | -120.78% |
Peers
Recent News
- Anteris Announces Upcoming Data Release for Medium-Size DurAVR THV from EMBARK Study at TCT 2026
- Anteris Technologies secures German clearance to expand PARADIGM heart valve trial
- Anteris Advances Global PARADIGM Trial Expansion with German Regulatory Clearance
- Anteris to Present at September Healthcare Investor Conferences
- Anteris Technologies Announces Results for the Second Quarter of 2026
Related
Browse more tickers: sitemap